Nuwellis Appoints Carisa Schultz as Chief Financial Officer
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE) announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz joins from NeueHealth, where she served as Vice President of Finance and led enterprise finance, treasury, and corporate development.
Her background includes roles at Boston Scientific and Big Four public accounting, bringing public-company healthcare and medical-technology finance experience to support Nuwellis’ next phase of growth.
Positive
- Appointing a CFO with public-company healthcare finance experience
- Start date set for February 2, 2026 enabling immediate leadership continuity
- Proven experience leading enterprise finance, treasury, and corporate development
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
NUWE gained 8.55% while key medical device peers were flat to down (e.g., VTAK -4.59%, VERO -4.72%, NAOV -1.95%), and only BJDX showed upside momentum. Moves appear company-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | Financing / warrants | Negative | +8.6% | $5M private placement and warrant inducement priced at-the-market. |
| Jan 29 | Acquisition deal | Positive | +8.6% | Agreement to acquire Rendiatech to expand real-time kidney monitoring. |
| Jan 23 | Board changes | Neutral | -3.1% | Resignations and appointments reshaping board with added governance expertise. |
| Jan 06 | Patent grant | Positive | +4.6% | New U.S. patent for pediatric extracorporeal therapy safety mechanisms. |
| Dec 09 | Clinical data | Positive | -1.3% | Lenox Hill study data supporting Aquadex use across critical-care settings. |
Recent NUWE news has produced mixed reactions: positive strategic or IP updates often aligned with gains, while financing and clinical/real‑world data sometimes saw divergent or negative moves.
Over the past several months, Nuwellis reported multiple strategic and financial developments. A $5.0 million private placement and a definitive agreement to acquire Rendiatech on Jan 29, 2026 coincided with a 8.55% move. Earlier, board refresh changes on Jan 21, 2026 and a new U.S. patent for pediatric extracorporeal therapy on Jan 6, 2026 highlighted governance and IP evolution. Real‑world Aquadex data shared on Dec 9, 2025 underscored clinical utility. Today’s CFO appointment fits into this broader period of capital raising, portfolio expansion, and governance reshaping.
Market Pulse Summary
This announcement highlights Nuwellis bringing in a CFO with public-company healthcare and medical technology finance experience as it advances precision cardiorenal care. It follows recent steps such as the Rendiatech acquisition agreement, a $5.0M private placement, and new pediatric-focused IP. Investors may track how the new finance leadership manages liquidity after a $15.099M year-to-date loss and $3.094M cash balance, as well as integration of new technologies into the cardiorenal platform.
Key Terms
cardiorenal medical
AI-generated analysis. Not financial advice.
Schultz brings public company healthcare finance and medical technology experience to support Nuwellis’ next phase of growth
MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026.
Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including Associate Vice President, Enterprise Finance and Director, Finance.
Ms. Schultz brings deep healthcare and medical technology finance experience, including early career experience at Boston Scientific, alongside leadership roles across public and private healthcare organizations. Her background also includes Big Four public accounting and senior financial analysis leadership roles supporting growth, operational discipline, and strategic decision-making.
“Carisa is a highly accomplished financial leader with strong public-company experience and a deep understanding of healthcare and medical technology,” said John Erb, Chief Executive Officer of Nuwellis. “Her expertise and disciplined approach will be instrumental as we continue to execute our strategy and advance our cardiorenal platform.”
“I’m excited to join Nuwellis at an important juncture in its growth,” said Ms. Schultz. “The company’s focus on precision cardiorenal care represents a meaningful opportunity, and I look forward to working with the leadership team to support long-term value creation.”
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company advancing precision fluid management technologies across the cardiorenal continuum. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations.
About the Aquadex SmartFlow® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com
FAQ
When does Carisa Schultz start as CFO of Nuwellis (NUWE)?
What experience does Carisa Schultz bring to Nuwellis (NUWE)?
How might the NUWE CFO appointment affect Nuwellis' financial leadership?
Was Carisa Schultz previously a public-company finance executive before joining NUWE?
What is Nuwellis' stated focus that the new CFO will support (NUWE)?
